Abstract
Hemophilia B (HB) is a rare X-linked congenital bleeding disorder characterized by a deficiency of coagulation factor IX (FIX). Diagnosed and undiagnosed prevalence rates per 100,000 males are 2.57 and 1.14 for HB in 2020, USA, respectively. Though HB affects only a small portion of population, it imposes high overall cost and financial burden on individuals, payers, and society in general. Current systematic literature review (SLR) aimed to summarize the economic burden reported in patients with HB.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
